Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

4.140 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
From AbCellera Biologics Inc.
Via Business Wire
News headline image
A Day Of Huge Market Moves ↗
It was a day of huge market moves and several reporting companies. Trudeau won but did not get a parliamentary majority. 
Via Talk Markets
News headline image
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
From AbCellera Biologics Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Analyzing AbCellera Biologics's Unusual Options Activity ↗
Shares of AbCellera Biologics (NASDAQ:ABCL) saw some unus... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
News headline image
15 Stocks Moving in Friday's Pre-Market Session ↗
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) rose 42% to $3.21 in pre-market trading. AbCellera Biologics Inc. (NASDAQ: ABCL) rose 18% to $23.35 in pre-market trading.... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
News headline image
AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody ↗
The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in... 
Via Benzinga
News headline image
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Why AbCellera Biologics Stock Jumped 7% on Wednesday ↗
The company's drug-development technology is starting to attract attention. 
Via The Motley Fool
News headline image
AbCellera Shares Are Moving Higher On Licensing Pact With Moderna ↗
AbCellera Biologics Inc (NASDAQ: ABCL) has entered into a research collaboration and license agreement with Moderna Inc (NASDAQ: MRNA) for antibodies for... 
Via Benzinga
News headline image
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
From AbCellera
Via Business Wire
News headline image
A Weak Week ↗
Chinese car-maker Nio appears to have been able to weather the Beijing crackdown on foreign listed firms better than later entrants. 
Via Talk Markets
News headline image
Here's Why AbCellera Biologics Stock Gained 10.6% Last Month ↗
Even with its recent gains, the biotech stock is down roughly 53.4% in 2021's trading. 
Via The Motley Fool
News headline image
Why AbCellera Biologics Stock Was Up More Than 17% on Friday ↗
The biopharma company's second quarter was better than expected. The future looks pretty bright, too. 
Via The Motley Fool
News headline image
AbCellera Biologics Inc. (ABCL) Q2 2021 Earnings Call Transcript ↗
ABCL earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
AbCellera Reports Q2 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
78 Biggest Movers From Friday ↗
Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering. Flora Growth... 
Via Benzinga
News headline image
More Greek Variants To Follow ↗
Nokia will supply the Western Power District with private long-term evolution fast 5G grid for trials. 
Via Talk Markets
News headline image
53 Stocks Moving In Friday's Mid-Day Session ↗
Gainers BIOLASE, Inc. (NASDAQ: BIOL) shares climbed 30.9% to $0.8270 after the company reported better-than-expected Q2 sales. The company said it continues to experience demand... 
Via Benzinga
News headline image
Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021? ↗
One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail. 
Via The Motley Fool
News headline image
Billionaire Masayoshi Son's SoftBank Claims $5B Stake In Roche: Bloomberg ↗
SoftBank Group Corp (OTC: SFTBF) has quietly acquired a $5 billion stake in Roche Holdings AG (OTC: RHHBF), making it one of the largest investors of the Roche,... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer
From Tachyon Therapeutics, Inc.
Via Business Wire
News headline image
Analyzing AbCellera Biologics's Unusual Options Activity ↗
AbCellera Biologics (NASDAQ:ABCL) shares experienced unusual options activity on Thursday. The stock price moved up to $16.32 following the option alert. Sentiment: BEARISH... 
Via Benzinga
News headline image
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.